Evidence map›Paper›PMID 29652098›Full record

ArticleJournal of the International AIDS Society2018

Monitoring progress towards the first UNAIDS target: understanding the impact of people living with HIV who re-test during HIV-testing campaigns in rural Mozambique.

Laura Fuente-Soro, Elisa Lopez-Varela, Orvalho Augusto, Charfudin Sacoor, Ariel Nhacolo, Nely Honwana, Esmeralda Karajeanes, Paula Vaz, Denise Naniche

Abstract read
In one paragraph

Article in Journal of the International AIDS Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Laura Fuente-SoroCentro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.ORCID 0000-0002-8580-5857
Elisa Lopez-VarelaCentro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.ORCID 0000-0002-6725-5687
Orvalho AugustoCentro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.
Charfudin SacoorCentro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.
Ariel NhacoloCentro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.
Nely HonwanaCentre for Disease Control and Prevention (CDC), Maputo, Mozambique.
Esmeralda KarajeanesFundação Ariel Glaser Contra o SIDA Pediátrico, Maputo, Mozambique.
Paula VazFundação Ariel Glaser Contra o SIDA Pediátrico, Maputo, Mozambique.
Denise NanicheCentro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.ORCID 0000-0002-4495-6325

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAwareness of HIV-infection goes beyond diagnosis, and encompasses understanding, acceptance, disclosure and initiation of the HIV-care. We aimed to characterize the HIV-positive population that underwent repeat HIV-testing without disclosing their serostatus and the impact on estimates of the first UNAIDS 90 target.

methodsThis analysis was nested in a prospective cohort established in southern Mozambique which conducted three HIV-testing modalities: voluntary counselling and testing (VCT), provider-initiated counselling and testing (PICT) and home-based testing (HBT). Participants were given the opportunity to self-report their status to lay counsellors and HIV-positive diagnoses were verified for previous enrolment in care. This study included 1955 individuals diagnosed with HIV through VCT/PICT and 11,746 participants of a HBT campaign. Those who did not report their serostatus prior to testing, and were found to have a previous HIV-diagnosis, were defined as non-disclosures. Venue-stratified descriptive analyses were performed and factors associated with non-disclosure were estimated through log-binomial regression.

resultsIn the first round of 2500 adults randomized for HBT, 1725 were eligible for testing and 18.7% self-reported their HIV-positivity. Of those tested with a positive result, 38.9% were found to be non-disclosures. Similar prevalence of non-disclosures was found in clinical-testing modalities, 29.4% (95% CI 26.7 to 32.3) for PICT strategy and 13.0% (95% CI 10.9 to 15.3) for VCT. Prior history of missed visits (adjusted prevalence ratio (APR) 4.2, 95% CI 2.6 to 6.8), younger age (APR 2.5, 95% CI 1.4 to 4.4) and no prior history of treatment ((APR) 1.4, 95% CI 1.0 to 2.1) were significantly associated with non-disclosure as compared to patients who self-reported. When considering non-disclosures as people living with HIV (PLWHIV) aware of their HIV-status, the proportion of PLWHIV aware increased from 78.3% (95% CI 74.2 to 81.6) to 86.8% (95% CI 83.4 to 89.6).

conclusionMore than one-third of individuals testing HIV-positive did not disclose their previous positive HIV-diagnosis to counsellors. This proportion varied according to testing modality and age. In the absence of an efficient and non-anonymous tracking system for HIV-testers, repeat testing of non-disclosures leads to wasted resources and may distort programmatic indicators. Developing interventions that ensure appropriate psychosocial support are needed to encourage this population to disclose their status and optimize scarce resources.

Indexed as

AdultAgedCounselingDisclosureFemaleHIV InfectionsHumansMaleMiddle AgedMozambiqueProspective StudiesRural Population90-90-90 targetsAwarenessDisclosureHIV care continuumHIV retestingLinkage to careMozambiquePublic healthSub-Saharan Africa

Identifiers

PMID29652098
PMCPMC5898226

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.